Article | July 9, 2021

Enabling Broader Adoption Of Process Intensification In Biopharma

Source: Sartorius

By Ganesh Kumar, Sartorius

PI Clean

PI is becoming increasingly well-understood and its utility is continuously evolving to meet specific manufacturer needs, from product development to manufacturing, whether approached stepwise or end-to-end.

The benefits of process intensification (PI) in biopharmaceutical manufacturing are well established: PI enables manufacturers to increase volumetric productivity, reduce timelines, decrease facility footprint, lower costs, or improve flexibility. However, knowledge about PI implementation — from the costs to the technological and regulatory aspects, and risk mitigation — is less ubiquitous.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online